180 related articles for article (PubMed ID: 31189618)
1. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
Strosberg J; Joish VN; Giacalone S; Perez-Olle R; Fish-Steagall A; Kapoor K; Dharba S; Lapuerta P; Benson AB
Oncologist; 2019 Nov; 24(11):1446-1452. PubMed ID: 31189618
[TBL] [Abstract][Full Text] [Related]
2. Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study.
Benson AB; Strosberg J; Joish VN; Dharba S; Sapre D; Lapuerta P
Pancreas; 2020 Mar; 49(3):408-412. PubMed ID: 32132510
[TBL] [Abstract][Full Text] [Related]
3. Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study.
Kulke MH; Kennecke HF; Murali K; Joish VN
Cancer Manag Res; 2021; 13():7439-7446. PubMed ID: 34611437
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
Anthony LB; Kulke MH; Caplin ME; Bergsland E; Öberg K; Pavel M; Hörsch D; Warner RRP; O'Dorisio TM; Dillon JS; Lapuerta P; Kassler-Taub K; Jiang W
Oncologist; 2019 Aug; 24(8):e662-e670. PubMed ID: 30651397
[TBL] [Abstract][Full Text] [Related]
5. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Pavel M; Gross DJ; Benavent M; Perros P; Srirajaskanthan R; Warner RRP; Kulke MH; Anthony LB; Kunz PL; Hörsch D; Weickert MO; Lapuerta P; Jiang W; Kassler-Taub K; Wason S; Fleming R; Fleming D; Garcia-Carbonero R
Endocr Relat Cancer; 2018 Mar; 25(3):309-322. PubMed ID: 29330194
[TBL] [Abstract][Full Text] [Related]
6. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
Kulke MH; Hörsch D; Caplin ME; Anthony LB; Bergsland E; Öberg K; Welin S; Warner RR; Lombard-Bohas C; Kunz PL; Grande E; Valle JW; Fleming D; Lapuerta P; Banks P; Jackson S; Zambrowicz B; Sands AT; Pavel M
J Clin Oncol; 2017 Jan; 35(1):14-23. PubMed ID: 27918724
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.
Anthony L; Ervin C; Lapuerta P; Kulke MH; Kunz P; Bergsland E; Hörsch D; Metz DC; Pasieka J; Pavlakis N; Pavel M; Caplin M; Öberg K; Ramage J; Evans E; Yang QM; Jackson S; Arnold K; Law L; DiBenedetti DB
Clin Ther; 2017 Nov; 39(11):2158-2168. PubMed ID: 29074312
[TBL] [Abstract][Full Text] [Related]
8. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
Weickert MO; Kaltsas G; Hörsch D; Lapuerta P; Pavel M; Valle JW; Caplin ME; Bergsland E; Kunz PL; Anthony LB; Grande E; Öberg K; Welin S; Lombard-Bohas C; Ramage JK; Kittur A; Yang QM; Kulke MH
Clin Ther; 2018 Jun; 40(6):952-962.e2. PubMed ID: 29724499
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs.
Joish VN; Frech F; Lapuerta P
J Med Econ; 2018 Feb; 21(2):182-188. PubMed ID: 28959913
[TBL] [Abstract][Full Text] [Related]
10. Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.
Dillon JS; Chandrasekharan C
Future Oncol; 2018 May; 14(12):1155-1164. PubMed ID: 29350062
[TBL] [Abstract][Full Text] [Related]
11. Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective.
Joish VN; Frech F; Lapuerta P
Clin Ther; 2017 Dec; 39(12):2338-2344. PubMed ID: 29175096
[TBL] [Abstract][Full Text] [Related]
12. Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Masab M; Saif MW
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1055-1062. PubMed ID: 29051994
[TBL] [Abstract][Full Text] [Related]
13. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
Kulke MH; O'Dorisio T; Phan A; Bergsland E; Law L; Banks P; Freiman J; Frazier K; Jackson J; Yao JC; Kvols L; Lapuerta P; Zambrowicz B; Fleming D; Sands A
Endocr Relat Cancer; 2014 Oct; 21(5):705-14. PubMed ID: 25012985
[TBL] [Abstract][Full Text] [Related]
14. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.
Dillon JS; Kulke MH; Hörsch D; Anthony LB; Warner RRP; Bergsland E; Welin S; O'Dorisio TM; Kunz PL; McKee C; Lapuerta P; Banks P; Pavel M
J Gastrointest Cancer; 2021 Mar; 52(1):212-221. PubMed ID: 32146619
[TBL] [Abstract][Full Text] [Related]
15. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial.
Pavel M; Hörsch D; Caplin M; Ramage J; Seufferlein T; Valle J; Banks P; Lapuerta P; Sands A; Zambrowicz B; Fleming D; Wiedenmann B
J Clin Endocrinol Metab; 2015 Apr; 100(4):1511-9. PubMed ID: 25636046
[TBL] [Abstract][Full Text] [Related]
16. Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues.
Kasi PM
Drugs Today (Barc); 2018 Jul; 54(7):423-432. PubMed ID: 30090879
[TBL] [Abstract][Full Text] [Related]
17. Telotristat ethyl: a new option for the management of carcinoid syndrome.
Lamarca A; Barriuso J; McNamara MG; Hubner RA; Valle JW
Expert Opin Pharmacother; 2016 Dec; 17(18):2487-2498. PubMed ID: 27817224
[TBL] [Abstract][Full Text] [Related]
18. Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea.
Lyseng-Williamson KA
Drugs; 2018 Jun; 78(9):941-950. PubMed ID: 29931594
[TBL] [Abstract][Full Text] [Related]
19. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR.
Cella D; Beaumont JL; Hudgens S; Marteau F; Feuilly M; Houchard A; Lapuerta P; Ramage J; Pavel M; Hörsch D; Kulke MH
Clin Ther; 2018 Dec; 40(12):2006-2020.e2. PubMed ID: 30477789
[TBL] [Abstract][Full Text] [Related]
20. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.
Fust K; Maschio M; Kohli M; Singh S; Pritchard DM; Marteau F; Myrenfors P; Feuilly M
Pharmacoeconomics; 2020 Jun; 38(6):607-618. PubMed ID: 32157590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]